228 related articles for article (PubMed ID: 26611431)
1. Balancing Early Aggression Against Risk of Progression in Multiple Sclerosis.
Duquette P; Giacomini PS; Bhan V; Hohol M; Schecter R
Can J Neurol Sci; 2016 Jan; 43(1):33-43. PubMed ID: 26611431
[TBL] [Abstract][Full Text] [Related]
2. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Application of Monoclonal Antibodies in Multiple Sclerosis.
Orthmann-Murphy JL; Calabresi PA
Clin Pharmacol Ther; 2017 Jan; 101(1):52-64. PubMed ID: 27804128
[TBL] [Abstract][Full Text] [Related]
4. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
Bates D
Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
[TBL] [Abstract][Full Text] [Related]
5. Clinically isolated syndromes: predicting and delaying multiple sclerosis.
Thrower BW
Neurology; 2007 Jun; 68(24 Suppl 4):S12-5. PubMed ID: 17562845
[TBL] [Abstract][Full Text] [Related]
6. The management of pediatric multiple sclerosis.
Yeh EA; Weinstock-Guttman B
J Child Neurol; 2012 Nov; 27(11):1384-93. PubMed ID: 22914373
[TBL] [Abstract][Full Text] [Related]
7. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
8. Predicting and preventing the future: actively managing multiple sclerosis.
Hutchinson M
Pract Neurol; 2009 Jun; 9(3):133-43, discussion 144. PubMed ID: 19448055
[TBL] [Abstract][Full Text] [Related]
9. [Multiple sclerosis at the time of world-wide use of disease modifying treatment].
Gusev EI; Boĭko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7 Suppl 2):4-9. PubMed ID: 19894306
[TBL] [Abstract][Full Text] [Related]
10. Natural history of multiple sclerosis: have available therapies impacted long-term prognosis?
Trojano M; Paolicelli D; Tortorella C; Iaffaldano P; Lucchese G; Di Renzo V; D'Onghia M
Neurol Clin; 2011 May; 29(2):309-21. PubMed ID: 21439443
[TBL] [Abstract][Full Text] [Related]
11. Emerging immunopharmacological targets in multiple sclerosis.
Farjam M; Zhang GX; Ciric B; Rostami A
J Neurol Sci; 2015 Nov; 358(1-2):22-30. PubMed ID: 26440421
[TBL] [Abstract][Full Text] [Related]
12. Multiple sclerosis in childhood and adolescence.
Tenembaum S
J Neurol Sci; 2011 Dec; 311 Suppl 1():S53-7. PubMed ID: 22206768
[TBL] [Abstract][Full Text] [Related]
13. Novel immunomodulatory approaches for the management of multiple sclerosis.
Kantarci OH; Pirko I; Rodriguez M
Clin Pharmacol Ther; 2014 Jan; 95(1):32-44. PubMed ID: 24173041
[TBL] [Abstract][Full Text] [Related]
14. A practical approach to immunomodulatory therapy for multiple sclerosis.
Burks JS
Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681
[TBL] [Abstract][Full Text] [Related]
15. Established and novel disease-modifying treatments in multiple sclerosis.
Cross AH; Naismith RT
J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
[TBL] [Abstract][Full Text] [Related]
16. Does interferon beta therapy affect survival of multiple sclerosis patients?
Kułakowska A; Drozdowski W
Neurol Neurochir Pol; 2014; 48(6):436-41. PubMed ID: 25482255
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing.
Craddock J; Markovic-Plese S
Expert Rev Clin Pharmacol; 2015 May; 8(3):283-96. PubMed ID: 25916665
[TBL] [Abstract][Full Text] [Related]
18. Relationship of immunologic abnormalities and disease stage in multiple sclerosis: implications for therapy.
Vaknin-Dembinsky A; Weiner HL
J Neurol Sci; 2007 Aug; 259(1-2):90-4. PubMed ID: 17521671
[TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis- diagnosis, management and prognosis.
Tsang BK; Macdonell R
Aust Fam Physician; 2011 Dec; 40(12):948-55. PubMed ID: 22146321
[TBL] [Abstract][Full Text] [Related]
20. Mode of action and clinical studies with fumarates in multiple sclerosis.
Salmen A; Gold R
Exp Neurol; 2014 Dec; 262 Pt A():52-6. PubMed ID: 24568735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
